Title:
A Phase III Clinical Trial for Test Use and Document Creation Only
Indication:
Miscellaneous
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
View
Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
View
Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Pac-Carbo-Oreg EO FT or PC
View
Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Pac-Carbo-Oreg EO FT or PC
View
Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
COMET: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
COMET: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
COMET: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
COMET: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
COMET: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Pac-Carbo-Oreg EO FT or PC
View
Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III